Blair William & Co. IL Sells 77,310 Shares of Edwards Lifesciences Co. (NYSE:EW)

Blair William & Co. IL reduced its position in Edwards Lifesciences Co. (NYSE:EW) by 12.8% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 526,292 shares of the medical research company’s stock after selling 77,310 shares during the period. Blair William & Co. IL’s holdings in Edwards Lifesciences were worth $38,961,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in Edwards Lifesciences by 10.4% during the fourth quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after buying an additional 6,537,494 shares during the last quarter. Wellington Management Group LLP grew its position in shares of Edwards Lifesciences by 86.3% during the 3rd quarter. Wellington Management Group LLP now owns 31,532,725 shares of the medical research company’s stock valued at $2,080,845,000 after acquiring an additional 14,610,123 shares during the period. State Street Corp increased its stake in shares of Edwards Lifesciences by 1.0% in the 3rd quarter. State Street Corp now owns 26,265,633 shares of the medical research company’s stock worth $1,733,270,000 after purchasing an additional 256,538 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Edwards Lifesciences by 2.2% in the 3rd quarter. Geode Capital Management LLC now owns 13,521,147 shares of the medical research company’s stock worth $889,050,000 after purchasing an additional 284,918 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Edwards Lifesciences by 7.7% during the fourth quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company’s stock valued at $723,664,000 after purchasing an additional 696,965 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company’s stock, valued at $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Bernard J. Zovighian sold 6,164 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total transaction of $428,459.64. Following the transaction, the chief executive officer now owns 59,083 shares in the company, valued at $4,106,859.33. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 62,553 shares of company stock valued at $4,513,064 over the last ninety days. 1.29% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on the company. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price target for the stock from $82.00 to $90.00 in a research report on Monday, December 16th. Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $68.00 to $71.00 and gave the stock a “hold” rating in a research note on Thursday, February 13th. Truist Financial reaffirmed a “hold” rating and set a $78.00 price target (up previously from $70.00) on shares of Edwards Lifesciences in a report on Thursday, December 5th. Stifel Nicolaus raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and increased their price objective for the stock from $75.00 to $90.00 in a research note on Thursday, January 30th. Finally, Barclays lifted their target price on shares of Edwards Lifesciences from $88.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, February 13th. One equities research analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $79.95.

Edwards Lifesciences Stock Up 0.1 %

NYSE EW opened at $71.17 on Friday. The stock has a 50 day moving average price of $71.47 and a 200-day moving average price of $70.46. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $96.12. The company has a market capitalization of $41.84 billion, a P/E ratio of 10.21, a P/E/G ratio of 4.82 and a beta of 1.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%. As a group, equities analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.